References
- Ahn J, Hayes RB. Environmental influences on the human microbiome and implications for noncommunicable disease. Annu Rev Public Health. 2021;42:277–292.
- Hernández-Chirlaque C, Aranda CJ, Ocón B, et al. Germ-free and antibiotic-treated mice are highly susceptible to epithelial injury in DSS colitis. J Crohns Colitis. 2016;10:1324–1335.
- Volkmann ER, Hoffmann-Vold AM. Gastrointestinal tract microbiota modifications in systemic sclerosis. Eur J Rheumatol. 2020;7:S228–36.
- Andréasson K, Lee SM, Lagishetty V, et al. Disease features and gastrointestinal microbial composition in patients with systemic sclerosis from two independent cohorts. ACR Open Rheumatol. 2022;4:417–425.
- Volkmann ER, Chang YL, Barroso N, et al. Association of systemic sclerosis with a unique colonic microbial consortium. Arthritis Rheumatol. 2016;68:1483–1492.
- Volkmann ER, Hoffmann-Vold AM, Chang YL, et al. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterol. 2017;4:e000134.
- Andréasson K, Alrawi Z, Persson A, et al. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease. Arthritis Res Ther. 2016;18:278.
- Patrone V, Puglisi E, Cardinali M, et al. Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement. Sci Rep. 2017;7:14874.
- Bellocchi C, Fernández-Ochoa Á, Montanelli G, et al. Microbial and metabolic multi-omic correlations in systemic sclerosis patients. Ann N Y Acad Sci. 2018;1421:97–109.
- Henke MT, Kenny DJ, Cassilly CD, et al. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn’s disease, produces an inflammatory polysaccharide. Proc Natl Acad Sci U S A. 2019;116:12672–12677.
- Volkmann ER, Hoffmann-Vold A-M, Chang Y-L, et al. Longitudinal characterisation of the gastrointestinal tract microbiome in systemic sclerosis. EMJ Rheumatology. 2020;5. 110–118.
- Waclawiková B, Codutti A, Alim K, et al. Gut microbiota-motility interregulation: insights from in vivo, ex vivo and in silico studies. Gut Microbes. 2022;14:1997296.
- Levin D, De Palma G, Zou H, et al. Fecal microbiome differs between patients with systemic sclerosis with and without small intestinal bacterial overgrowth. J Scleroderma Relat Disord. 2021;202(6):290–298
- Silk DB, Davis A, Vulevic J, et al. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:8–508.
- Low AHL, Teng GG, Pettersson S, et al. A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease. Semin Arthritis Rheum. 2019;49:411–419.
- Marighela TF, Arismendi MI, Marvulle V, et al. Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial. Rheumatology (Oxford). 2019;58:1985–1990.
- Howlett N, Lee S, Lagishetty V, et al. A low FODMAP diet is not associated with decreased GI symptoms or changes in GI microbial composition in patients with systemic sclerosis [Abstract]. Arthritis Rheumatol. 2020;72(Suppl 10).
- Fretheim H, Chung BK, Didriksen H, et al. Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial. PLoS One. 2020;15:e0232739.
- Polkowska-Pruszyńska B, Gerkowicz A, Rawicz-Pruszyński K, et al. Gut microbiome in systemic sclerosis: a potential therapeutic target. Postepy Dermatol Alergol. 2022;39:101–109.